Table 3 ROC AUC (95% CI) for sputum and serum mediators between all stable and all exacerbation visits
| Â | Sputum | Serum |
|---|---|---|
(Stable = 187; Exacerbation = 44) | (Stable = 228; Exacerbation = 52) | |
IL-1α | 0.50 (0.39 to 0.62) | BLQ |
IL-1β | 0.59 (0.49 to 0.70) | 0.43 (0.35 to 0.51) |
IL-2 | 0.57 (0.47 to 0.68) | BLQ |
IL-5 | 0.50 (0.41 to 0.60) | 0.49 (0.49 to 0.50) |
IL-6 | 0.61 (0.52 to 0.71) | BLQ |
IL-6R | 0.68 (0.58 to 0.78) | ALQ |
IL-8 | 0.59 (0.50 to 0.68) | 0.50 (0.40 to 0.59) |
IL-15 | 0.59 (0.48 to 0.69) | BLQ |
IL-18 | 0.62 (0.52 to 0.72) | 0.60 (0.52 to 0.69) |
CXCL9 | 0.65 (0.55 to 0.74) | 0.60 (0.51 to 0.69) |
CXCL10 | 0.60 (0.50 to 0.70) | 0.61 (0.52 to 0.70) |
CXCL11 | 0.53 (0.43 to 0.64) | 0.66 (0.57 to 0.76) |
CCL2 | 0.57 (0.47 to 0.67) | 0.44 (0.35 to 0.54) |
CCL3 | 0.49 (0.38 to 0.59) | BLQ |
CCL4 | 0.57 (0.47 to 0.67) | 0.48 (0.39 to 0.57) |
CCL5 | 0.67 (0.56 to 0.77) | ALQ |
CCL11 | 0.45 (0.36 to 0.55) | 0.50 (0.41 to 0.60) |
CCL13 | 0.44 (0.36 to 0.52) | ALQ |
CCL17 | 0.42 (0.33 to 0.51) | 0.52 (0.43 to 0.60) |
CCL26 | 0.50 (0.41 to 0.59) | 0.52 (0.42 to 0.62) |
TNFα | 0.64 (0.54 to 0.74) | 0.52 (0.43 to 0.61) |
TNF-R1 | 0.63 (0.53 to 0.73) | 0.50 (0.41 to 0.59) |
TNF-R2 | 0.69 (0.60 to 0.78) | BLQ |
VEGF | 0.51 (0.41 to 0.62) | 0.49 (0.40 to 0.58) |
EGF | 0.50 (0.40 to 0.59) | 0.46 (0.36 to 0.55) |
SCF | BLQ | 0.52 (0.44 to 0.60) |
ST2 | BLQ | 0.56 (0.47 to 0.66) |
CHTR | 0.64 (0.53 to 0.74) | 0.46 (0.36 to 0.55) |
Periostin | Not done | 0.52 (0.46 to 0.58) |
DDP4 | Not done | 0.41 (0.32 to 0.50) |